High-Level Production and Purification of P30P2MSP119, an Important Vaccine Antigen for Malaria, Expressed in the Methylotropic Yeast Pichia pastoris

Brady, Conor; Shimp, Richard L.; Miles, Aaron P.; Whitmore, Michael D.; Stowers, Anthony W.

doi:10.1006/prep.2001.1526

Cited by 56 publications

(53 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our preliminary results agree with Brady et al (2001), who reported higher yields of recombinant P30P2mSP1 19 with decreasing cation levels in the medium. Modifi cations to the basal salts and the levels of PTM4 salts resulted in a signifi cant increase in process productivity on both a per-liter and, more signifi cantly, a per-vessel basis.…”

Section: Discussionsupporting

confidence: 92%

Pichia pastoris fermentation optimization: energy state and testing a growth-associated model

Plantz

Sinha

Villarete³

et al. 2006

Appl Microbiol Biotechnol

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 92%

Pichia pastoris fermentation optimization: energy state and testing a growth-associated model

Plantz

Sinha

Villarete³

et al. 2006

Appl Microbiol Biotechnol

View full text Add to dashboard Cite

show abstract

“…The recombinant protein was expressed in Pichia pastoris as a fusion protein with the P30 and P2 universal T epitopes [27]. The inclusion of the universal T helper epitopes was to insure that any observed differences in immunogenicity is not due to preferential recognition of T epitopes regulated by immune response (IR) genes [28].…”

Section: Malaria Vaccine Antigenmentioning

confidence: 99%

“…The inclusion of the universal T helper epitopes was to insure that any observed differences in immunogenicity is not due to preferential recognition of T epitopes regulated by immune response (IR) genes [28]. The purification of P30P2MSP1-19 was described previously [27], and this antigen was a kind gift from Dr. Anthony Stowers.…”

Section: Malaria Vaccine Antigenmentioning

confidence: 99%

Interleukin-6 has differential influence on the ability of adjuvant formulations to potentiate antibody reponses to a Plasmodium falciparum blood-stage vaccine

Hui

Hashimoto

2007

Vaccine

View full text Add to dashboard Cite

The efficacy of vaccine adjuvants can be influenced by the immunological environment of the host, depending on the mechanism(s) by which they exert their immunopotentiating activities. Interleukin-6 is a pleiotropic cytokine that has a broad range of biological activities on immune and non-immune cells. We investigated the role of IL-6 on the ability of nine adjuvant formulations to induce antibody responses to the P. falciparum MSP1-19 malaria vaccine, using IL-6 -/-(KO) mice. Results showed that some adjuvants, ie. MPL-SE, CFA/IFA, ISA720/QS21/MPL, depended on IL-6 for their efficacy, while others exhibited increased potency in its absence. The efficacy of adjuvants in the IL-6 KO environment cannot be solely attributed to their ability to stimulate antigen-specific cellular responses, suggesting that other biological activities of IL-6 are also important. The results further suggest that two adjuvants utilized dissimilar pathways to potentiate the same type of immune response.

show abstract

Section: Malaria Vaccine Antigenmentioning

confidence: 99%

“…The recombinant protein was expressed in Pichia pastoris as a fusion protein with the P30 and P2 universal T epitopes [30]. The production and purification of this vaccine antigen was described in detail in a previous study [30]. The utilization of the recombinant antigen with universal T helper epitopes was to help insure that any observed differences in immunogenicity is not due to preferential recognition of T epitopes regulated by immune response (IR) genes [31].…”

Section: Malaria Vaccine Antigenmentioning

confidence: 99%

Adjuvant formulations possess differing efficacy in the potentiation of antibody and cell mediated responses to a human malaria vaccine under selective immune genes knockout environment

Hui¹,

Hashimoto²

2008

International Immunopharmacology

View full text Add to dashboard Cite

Infections and chronic diseases can alter the host's immunological balance or result in immunodeficiencies. We hypothesize that this may also affect the performance of vaccine adjuvants. Accordingly, the potency and adjuvanticity of eight adjuvant formulations based on Montanide ISA720, MF59, monophosphoryl lipid A (MPL), QS21 (saponin derivative), MPL-SE (stable emulsion of a MPL derivative), and MPL-AF (MPL in aqueous formulation) were studied in immune gene knockout mice, IFN-γ −/−, IL-4 −/−, and STAT6 −/−, using the P. falciparum MSP1 vaccine, P30P2MSP1-19 as a model immunogen. The adjuvants showed preferential requirements for the immune mediators to induce immune responses to MSP1-19, and the effects were formulationspecific. While emulsion-type adjuvants were highly effective in mice, their potency was more readily suppressed by immune knockouts; and additions of immunomodulators were required to restore efficacy. Formulated adjuvants had characteristics distinct from their individual components, and multi-components formulations were not necessarily superior. We conclude that perturbation of immune environments will have measurable impact on adjuvant's potency. Evaluation of adjuvants in immune knockout models may be a supplementary approach to measure and compare adjuvants' efficacy, and to further unveil their distinct biological activities.

show abstract

High-Level Production and Purification of P30P2MSP119, an Important Vaccine Antigen for Malaria, Expressed in the Methylotropic Yeast Pichia pastoris

Cited by 56 publications

References 21 publications

Pichia pastoris fermentation optimization: energy state and testing a growth-associated model

Pichia pastoris fermentation optimization: energy state and testing a growth-associated model

Interleukin-6 has differential influence on the ability of adjuvant formulations to potentiate antibody reponses to a Plasmodium falciparum blood-stage vaccine

Adjuvant formulations possess differing efficacy in the potentiation of antibody and cell mediated responses to a human malaria vaccine under selective immune genes knockout environment

Contact Info

Product

Resources

About